Practice of setting the price of a biosimilar medicine, in relationship to the reference medicine price, usually at a certain percentage lower than the reference medicine price. The design of the price link policy may vary, with different percentages for the different following biosimilar products (first follower coming to the market, second follower, etc.), and in some cases the prices of reference medicines might also be part of the policy, i.e. that they will also be required to decrease.
Last update: 7 June 2023